What is ANIK's P/E ratio?

Anika Therapeutics Inc (ANIK) currently trades at a P/E ratio of 77.06.

Anika Therapeutics Inc reports a Return on Equity (ROE) of -2.76%.

What is ANIK's dividend yield?

Anika Therapeutics Inc offers a dividend yield of 0.00%.

What is ANIK's Quality Score?

Our AI rates ANIK's overall financial quality at 54 out of 100, based on profitability, growth, debt and earnings stability.

Is now a good time to buy ANIK?

Our AI Timing Score for ANIK is 91 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.

Which sector does ANIK belong to?

Anika Therapeutics Inc is classified under the Healthcare >> Drug Manufacturers - Specialty & Generic sector on the NASDAQ exchange

Anika Therapeutics Inc (ANIK) Stock Price

Stock Check Daily update data at 8:30 AM
(Price: 2026-08-04 | FS: 2026-06-30)

ANIK AI Analysis Summary

Our AI summary for ANIK: Anika Therapeutics Inc (NASDAQ), Healthcare >> Drug Manufacturers - Specialty & Generic sector. The stock currently trades at a P/E of 77.06, ROE of -2.76%, a dividend yield of 0.00%. Its financial Quality Score stands at 54/100 — mid-range fundamentals relative to the market. The AI Timing Score is 91/100 — multiple technical signals currently support price momentum. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

ANIK

Anika Therapeutics Inc

USD 19.61

-1.13 (-5.43%) Day Change

Watchlist Portfolio Compare Chart

77.06

P/E

0.34

D/E

-2.8%

ROE

-2.1%

ROA

0.00%

Div Yield

0.68

PEG

ANIKA THERAPEUTICS INC
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 19.61 Price -1.13 (-5.43%) Day Change	NEWS SCORE: 99

ANIK, the overall quality is not quite good ( Quality = 54) but the timing to buy is ...(Sign In to See)...

Loading chart...

54 QUALITY

Signal: UNDERPERFORM

Signal Description: Company financial health is Not Good

Reason: P/E ratio is relatively high
ROE is relatively low.
ROA is relatively low.
Historical ROE is relatively low
ROA is too relatively low compare to ROE
Net profit margin is relatively low.
Historical net profit margin is relatively low.

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

In details, quality factors are not good , financial health is not good , and ability to make profit is ok , ...

Quality Factors

45%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	99
Magic Formula Rank by ROA	N/A
Magic Formula Rank by ROE	N/A
Magic Formula Rank by ROIC	N/A
Price	19.61
PBV / Sector	2.02 / 10.04
Earning Per Share	-0.27

PE / Sector	77.06 / 32.60
PEG or PE/Growth / Sector	0.68 / -0.13
Average 1M Daily Value	1.51 M GREAT
Average 1W Daily Value	3.17 M GREAT

Timing Factors

85%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Financial Health

45%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

Ability to Make Profit

60%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	-3.14 / 12.55
NPM Average (%) / Sector	-27.55 / -10.76
NPM Change Average (%) / Sector	110.33 / 113.68 GREAT
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	-2.06 / 7.68
ROA Average (%) / Sector	-14.08 / 2.97
ROA Change Average (%) / Sector	116.35 / 111.24 GREAT
ROE (%) / Sector	-2.76 / 25.75
ROE Average (%) / Sector	-18.22 / 14.00
ROE Change Average (%) / Sector	124.88 / 377.43 GREAT
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

Return to Investors

Dividend (%) / Sector	N/A / 0.52
Dividend Average (%) / Sector	N/A / 3.06
Dividend Change Average (%) / Sector	N/A / 13.76

Registration Details

Analyze Date	2026-08-05 07:59:49
Symbol	ANIK
Name	ANIKA THERAPEUTICS INC
Sector	Healthcare >> Drug Manufacturers - Specialty & Generic
Market	NASDAQ
Listed Shares	13.38 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	277.50 / 10,527.15

News, Concensus, ...

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: 32 Wiggins Avenue, Bedford, MA, United States, 01730

Phone: 781 457 9000

Website: https://www.anika.com

Employees: 235

Sector: Healthcare >> Drug Manufacturers - Specialty & Generic

Description: Anika Therapeutics, Inc., a joint preservation company, focuses on early intervention orthopedics in the United States, Europe, and internationally. The company offers osteoarthritis (OA) pain management products and services, such as Monovisc and Orthovisc, which are single- and multi-injection, HA viscosupplement products indicated for pain relief from OA conditions, as well as Cingal, a non-opioid, single-injection OA pain management product; regenerative solutions, including an HA-based scaffold with bone and tendon fixation components and arthroscopic delivery instruments; Hyalofast, a resorbable scaffold used for single stage cartilage regeneration; and Tactoset injectable bone substitute, an HA-enhanced injectable bone repair therapy designed to treat insufficiency fractures and augment hardware fixation. It also provides Integrity, an HA-based scaffold with bone and tendon fixation components and arthroscopic delivery instruments; non-orthopedic products, including Hyvisc, a high molecular weight injectable HA veterinary product for the treatment of joint dysfunction in horses due to non-infectious synovitis associated with equine OA; Hyalobarrier, an anti-adhesion barrier indicated for use after abdominal-pelvic surgeries; and ophthalmic products; and Anikavisc and Nuvisc high molecular weight HA products. The company was founded in 1983 and is headquartered in Bedford, Massachusetts.